The Antithrombin Market is Expected to Foresee Significant Growth. The U.S. to lead the growth!

The antithrombin market is expected to witness a CAGR of around 5% during the forecast period. Antithrombin is produced by the liver, it is a protein present in blood that inhibits blood clotting by inactivating thrombin. antithrombin deficiency caused due to other diseases such as nephrotic syndrome, liver failure, severe trauma, metastatic tumors, and genetic mutation. Moreover, advancements in drug administering technology and rising diseases related to blood clotting are further contributing to the growth of this market. Additionally, antithrombin deficiency may lead to the risk of thromboembolism, which can result in excessive bleeding during surgical procedures. Antithrombin III is preferentially utilized for extracorporeal membrane oxygenation (ECMO) during cardiopulmonary bypass. For instance, according to the National Institutes of Health (NIH), around 310 million surgeries are performed each year in the U.S.

For a detailed analysis of the Antithrombin Market browse throughhttps://univdatos.com/report/antithrombin-market/

Based on application, the antithrombin market is segmented into therapeutic, research, and diagnostics. In 2020, the therapeutic category is anticipated to witness a lucrative growth rate during the forecast period. This is mainly due to the rising number of cardiac surgeries, research and development of drugs, and heart-related diseases such as atrial fibrillation, heart failure, etc. these factors increase demands for antithrombin in the therapeutic category. Moreover, antithrombic drugs and treatments have become an imperative part of the treatment of heart diseases. These factors will drive the growth of this segment during the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), it is estimated that 12.1 million people in the U.S. will have atrial fibrillation (AFib) in 2030

Based on source, the antithrombin market is segmented into the human, goat milk, and others. The goat milk category is supposed to witness considerable growth during the forecast period because of its proven medical efficacy. Goat milk is the main outside source of antithrombin, it can produce the same amount of antithrombin in a year as 90,000 blood donations. Moreover, the factors such as rising cases of blood clotting, high blood pressure, high cholesterol, and cardiac surgeries are further contributing to the growth of this market. Many key market players launching new products for the treatment of antithrombin deficiency.

Based on dosage form, the antithrombin market is categorized into lyophilized and liquid. The lyophilized category captured a significant share of the market and is anticipated to witness a considerable growth rate during the forecast period mainly owing to its application in the treatment of thrombin deficiency and coronary heart diseases (CAD). For instance, according to the Centers for Disease Control and Prevention (CDC), around 18.2 million adults and older have coronary artery disease. Moreover, lyophilized antithrombin is also used to treat venous thromboembolism (VTE) and peripheral artery diseases (PAD) which is an underdiagnosed and serious, yet preventable medical condition that can cause disability and death. Hence the market for the lyophilized category is expected to grow during the forecast period.

Request for Sample of the report browse throughhttps://univdatos.com/get-a-free-sample-form-php/?product_id=23070

For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of North America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific) and Rest of World. In 2020, North America accounted for a significant market share. The rising growth of this market in the region is mainly due to the heart disease patients in the region, the presence of a large population, the availability of skilled healthcare professionals, & major pharmaceutical companies. Further on, the increasing number of blood clots in the region is also contributing to the growth of this market in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S. as many as 100,000 people die of blood clots each year. Blood clots cost our nation up to $10 billion each year.

Some of the major companies operating in the antithrombin market include Grifols S.A., Octapharma AG, LFB USA Inc., CSL Limited, Takeda Pharmaceuticals, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma Inc.

Request for Sample of the report browse throughhttps://univdatos.com/get-a-free-sample-form-php/?product_id=23070

Antithrombin Market Segmentation

Market Insight, By Application

• Therapeutic
• Research
• Diagnostics

Market Insight, By Source

• Human
• Goat Milk
• Others

Market Insight, By Dosage Form

• Lyophilized
• Liquid

Market Insight, By Region

• North America Antithrombin Market
  • U.S.
  • Canada
  • Rest of North America
• Europe Antithrombin Market
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific Antithrombin Market
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World Antithrombin Market

Top Company Profiles

• Grifols S.A.
• Octapharma AG
• LFB USA Inc.
• CSL Limited
• Takeda Pharmaceuticals
• Axis-Shield Plc
• Siemens AG
• Thermo Fisher Scientific
• Lee Biosolutions Inc.
• BDI Pharma Inc